---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-122564"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:43:11.082754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix enters quiet period for SOL-1 Phase 3 trial; data on track Q1 2026

## Summary
- Quiet period for SOL-1 Phase 3 trial of AXPAXLI (wet AMD) begins December 20, 2025.
- Next investor communication expected early February 2026 with Q4/FY2025 results.
- SOL-1 data remain on track for release in the first quarter of 2026.
- No financial results or clinical data provided; no exhibits attached.

## SEC filing metadata
- accession: 0001104659-25-122564
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/0001104659-25-122564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/tm2533889d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-122564
- JSON: https://secwatch.observer/filing/0001104659-25-122564.json
- Plain text: https://secwatch.observer/filing/0001104659-25-122564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.